Literature DB >> 19386349

CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma.

William R Sukov1, Rhett P Ketterling, Donna J Lager, Austin W Carlson, Jason P Sinnwell, George K Chow, Robert B Jenkins, John C Cheville.   

Abstract

SUMMARY: Renal oncocytoma is a benign tumor occurring singly or as multiple synchronous lesions. The histologic features of renal oncocytoma may overlap with those of chromophobe renal cell carcinoma. Chromosomal translocations involving the CCND1 locus at 11q13 and overexpression of cyclin D1 occur in a subset of renal oncocytomas. We evaluated a series of 63 renal oncocytomas and 36 chromophobe renal cell carcinomas and assessed the clinical features, cyclin D1 overexpression by immunohistochemistry, and alterations of the CCND1 gene by fluorescence in situ hybridization. All 36 chromophobe renal cell carcinomas were negative for cyclin D1 overexpression and alterations of CCND1. Of the 63 renal oncocytomas, 21 (33%) showed cyclin D1 overexpression. Of 21 renal oncocytomas with cyclin D1 overexpression, a CCND1 rearrangement was detected in 12 (57%). A CCND1 rearrangement was also identified in 1 (2%) of the 42 renal oncocytomas without cyclin D1 overexpression. Of 42 renal oncocytomas without cyclin D1 overexpression, 16 (38%) were from patients with multiple renal oncocytomas at nephrectomy. Of 21 renal oncocytomas with cyclin D1 overexpression, only 1 (5%) patient had multiple renal oncocytomas (P = .006). Of the 25 patients whose original tumor showed no cyclin D1 overexpression, 8 (32%) developed a subsequent renal oncocytoma. None of 15 patients whose original tumor showed cyclin D1 overexpression had a subsequent renal oncocytoma (P = .016). The findings of this study suggest that renal oncocytomas lacking cyclin D1 overexpression may be associated with the development of multiple renal oncocytomas and that these patients are more likely to develop subsequent renal oncocytomas suggesting the need for more frequent clinical for these patients and little need for follow-up in patients with renal oncocytomas overexpressing cyclin D1. The data also show that cyclin D1 overexpression and CCND1 rearrangements by fluorescence in situ hybridization are absent in chromophobe renal cell carcinoma, suggesting that these are useful when differentiating between renal oncocytoma and chromophobe renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19386349     DOI: 10.1016/j.humpath.2009.01.016

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  11 in total

1.  C11orf95-MKL2 is the resulting fusion oncogene of t(11;16)(q13;p13) in chondroid lipoma.

Authors:  Dali Huang; Janos Sumegi; Paola Dal Cin; John D Reith; Taketoshi Yasuda; Marilu Nelson; David Muirhead; Julia A Bridge
Journal:  Genes Chromosomes Cancer       Date:  2010-09       Impact factor: 5.006

Review 2.  Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.

Authors:  Pierre Combe; Eleonore de Guillebon; Constance Thibault; Clémence Granier; Eric Tartour; Stéphane Oudard
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

3.  A new age for vaccine therapy in renal cell carcinoma.

Authors:  Sumanta K Pal; Adriana Hu; Robert A Figlin
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

4.  The contemporary role of renal mass biopsy in the management of small renal tumors.

Authors:  Amy Lim; Brock O'Neil; Marta E Heilbrun; Christopher Dechet; William T Lowrance
Journal:  Front Oncol       Date:  2012-09-10       Impact factor: 6.244

Review 5.  Modern Pathologic Diagnosis of Renal Oncocytoma.

Authors:  Sara E Wobker; Sean R Williamson
Journal:  J Kidney Cancer VHL       Date:  2017-10-09

6.  The baboon kidney transcriptome: analysis of transcript sequence, splice variants, and abundance.

Authors:  Kimberly D Spradling; Jeremy P Glenn; Roy Garcia; Robert E Shade; Laura A Cox
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

Review 7.  Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms.

Authors:  Ning Yi Yap; Retnagowri Rajandram; Keng Lim Ng; Jayalakshmi Pailoor; Ahmad Fadzli; Glenda Carolyn Gobe
Journal:  Biomed Res Int       Date:  2015-09-13       Impact factor: 3.411

8.  Subtyping of renal cortical neoplasms in fine needle aspiration biopsies using a decision tree based on genomic alterations detected by fluorescence in situ hybridization.

Authors:  Banumathy Gowrishankar; Lynnette Cahill; Alexandra E Arndt; Hikmat Al-Ahmadie; Oscar Lin; Kalyani Chadalavada; Seeta Chaganti; Gouri J Nanjangud; Vundavalli V Murty; Raju S K Chaganti; Victor E Reuter; Jane Houldsworth
Journal:  BJU Int       Date:  2014-07-15       Impact factor: 5.588

9.  The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis.

Authors:  Shilpy Joshi; Denis Tolkunov; Hana Aviv; Abraham A Hakimi; Ming Yao; James J Hsieh; Shridar Ganesan; Chang S Chan; Eileen White
Journal:  Cell Rep       Date:  2015-11-19       Impact factor: 9.423

Review 10.  Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach.

Authors:  Reza Alaghehbandan; Delia Perez Montiel; Ana Silvia Luis; Ondrej Hes
Journal:  Cancers (Basel)       Date:  2019-12-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.